# A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

> **NCT02019693** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** INC280

## Key facts

- **NCT ID:** NCT02019693
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-24
- **Primary completion:** 2021-12-17
- **Final completion:** 2021-12-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019693, "A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02019693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*